Oric Pharmaceuticals Inc (NASDAQ: ORIC) — Perfil da empresa, notícias e dados financeiros
Oric Pharmaceuticals focuses on developing targeted anti-cancer drugs to overcome treatment resistance in cancer therapy.
Oric Pharmaceuticals Inc
Oric Pharmaceuticals (NASDAQ:ORIC) is fully committed to the development and innovation of therapies aimed at overcoming resistance in cancer treatment. Based in the heart of the biotechnology sector, Oric Pharmaceuticals focuses on a robust pipeline of targeted anti-cancer drugs. These cutting-edge projects are designed to address the complex challenges faced by patients who have developed resistance to current cancer therapies. The objectives of Oric are deeply rooted in the belief that through scientific rigor and a dedicated approach to research, it is possible to unlock new pathways in oncology, providing hope and improved outcomes for patients facing this tough battle.
Resumo
Operações
Produtos e/ou serviços de Oric Pharmaceuticals Inc
- Developing ORIC-533 for multiple myeloma, targeting the cancer-causing proteins to inhibit tumor growth.
- Creating precision oncology treatments focusing on resistance mechanisms to current cancer therapies.
- Advancing ORIC-944, an allosteric inhibitor targeting the P300/CBP for prostate cancer treatment.
- Researching and developing therapies to overcome treatment-resistant cancer through novel scientific insights.
- Expanding the oncology portfolio with a focus on genetically defined cancers and resistance mechanisms.
- Offering comprehensive cancer treatment solutions by integrating advanced therapeutic options and personalized medicine.
equipe executiva do Oric Pharmaceuticals Inc
- Richard A. HeymanFounder, Independent Chairman & Member of Scientific Advisory Board
- Jacob M. ChackoPresident, CEO & Director
- Dominic G. PiscitelliChief Financial Officer
- Pratik S. MultaniChief Medical Officer
- Charles L. SawyersFounder & Member of Scientific Advisory Board
- Scott W. LoweFounder & Member of Scientific Advisory Board
- Kevin BrodbeckChief Technical Officer
- Lori Sickels FriedmanChief Scientific Officer
- Christian V. KuhlenGeneral Counsel
- Daniel IazzettiVP & Head of People
Últimas notícias sobre a Oric Pharmaceuticals Inc
Principais indicadores financeiros
Resultados divulgados pela Oric Pharmaceuticals Inc, em USD.
- Cap. de mercado
- 964 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -143 mi | -129,5 mi | |
| 0 | -142,9 mi | -127,8 mi | |
| 0 | -110,8 mi | -100,7 mi | |
| 0 | -91,8 mi | -89,1 mi |